SANUWAVE Health Issues Q1 Revenue Guidance of $9.6M-$10.3M Amid Financial Scrutiny
Summary
SANUWAVE Health has provided first-quarter revenue guidance, projecting sales between $9.6 million and $10.3 million. This guidance is particularly critical as it follows the company's recent 8-K filing on March 13, 2026, which advised investors not to rely on previously issued financial statements due to material misstatements. For a company of SANUWAVE's size, this revenue range represents a significant operational update. Traders will closely scrutinize these figures as they offer the first forward-looking financial insight since the disclosure of past financial unreliability, providing a new baseline for assessing the company's current performance and the credibility of its financial reporting moving forward. Investors will be watching for any further updates on the restatement process and how actual results compare to this new guidance.
At the time of this announcement, SNWV was trading at $18.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.7M. The 52-week trading range was $18.61 to $46.59. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.